Duchenne muscular dystrophy
Author:
- 1 October 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 28 (5) , 542-546
Abstract
This article reviewed the most recent clinical trials investigating potential treatments for Duchenne muscular dystrophy (DMD). In the development of these studies, investigators have encountered unexpected challenges that reveal limitations in our understanding of the clinical trial design for this disease. Recent clinical trials for DMD have revealed limitations in our understanding of the natural history of this disease. As a result of these revelations, there has been a significant effort to document the natural history of Duchenne and develop valid outcome measure that could be used in clinical trials in different subsets of patients. Treatment for DMD is a rapidly changing field. Some of the drugs that are currently under investigation will receive Food and Drug Administration approval in the near future. These would become part of clinical practice. This article summarizes the different therapeutic approaches under investigation and illustrates the importance of defining sound research methods that are specific to the disease and population under investigation.Keywords
This publication has 33 references indexed in Scilit:
- THE 6‐minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter studyMuscle & Nerve, 2013
- Tadalafil Alleviates Muscle Ischemia in Patients with Becker Muscular DystrophyScience Translational Medicine, 2012
- Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophyJournal of Neurology, 2012
- Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophyDevelopmental Medicine & Child Neurology, 2011
- Dystrophin Immunity in Duchenne's Muscular DystrophyNew England Journal of Medicine, 2010
- Reliability of the North Star Ambulatory Assessment in a multicentric settingNeuromuscular Disorders, 2009
- Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutationsHuman Mutation, 2009
- Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame ruleMuscle & Nerve, 2006
- Loss of myostatin attenuates severity of muscular dystrophy in mdx miceAnnals of Neurology, 2002
- An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locusGenomics, 1988